Song Jiang Ma
Directeur Général chez Continent Pharmaceutical Inc.
Profil
Song Jiang Ma is the founder of Beijing Kangdini Factory, which was founded in 1996.
He held the title of General Manager at the company.
Currently, Mr. Ma holds several positions.
He is the Chief Executive Officer & Executive Director at Continent Pharmaceutical Inc. since 2002.
He is also the General Manager & Executive Director at Beijing Continent Pharmaceutical Co., Ltd.
since 2002.
Additionally, he is an Executive Director & Manager at Beijing Jisheng Connor Network Technology Co. Ltd.
and the President & Director at Gyre Therapeutics, Inc. since 2023.
In the past, Mr. Ma served as the President & Director at Catalyst Biosciences, Inc. He was also a Director at Beijing Institute of Telecommunication & Computer Applications and Beijing Jisheng Kangning Medical Technology Development.
Furthermore, he worked as a Supervisor at Beijing Kangqiang Economic & Technical Co. Ltd.Mr. Ma's education includes an undergraduate degree from Beijing University of Posts & Telecommunications.
He also obtained a graduate degree from China Electric Power Research Institute Ltd.
in 1983.
Postes actifs de Song Jiang Ma
| Sociétés | Poste | Début |
|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Directeur Général | 01/07/2002 |
| Beijing Jisheng Connor Network Technology Co. Ltd. | Directeur/Membre du Conseil | - |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Directeur Général | 01/07/2011 |
Anciens postes connus de Song Jiang Ma
| Sociétés | Poste | Fin |
|---|---|---|
| CATALYST BIOSCIENCES | President | - |
| Beijing Kangdini Factory | Fondateur | - |
| Beijing Jisheng Kangning Medical Technology Development | Directeur/Membre du Conseil | - |
| Beijing Kangqiang Economic & Technical Co. Ltd. | Directeur/Membre du Conseil | - |
| Beijing Institute of Telecommunication & Computer Applications | Directeur/Membre du Conseil | - |
Formation de Song Jiang Ma
| Beijing University of Posts & Telecommunications | Undergraduate Degree |
| China Electric Power Research Institute Ltd. | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
| Beijing Jisheng Connor Network Technology Co. Ltd. | |
| Beijing Institute of Telecommunication & Computer Applications | |
| Beijing Jisheng Kangning Medical Technology Development | |
| Beijing Kangqiang Economic & Technical Co. Ltd. | |
| Beijing Kangdini Factory |
